Organigram Global (NASDAQ:OGI) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Organigram Global (NASDAQ:OGI) posted its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04), Zacks reports. Organigram Global had a net margin of 28.14% and a negative return on equity of 14.52%. The company had revenue of $76.41 million for the quarter, compared to analysts’ expectations of $68.20 million.

Here are the key takeaways from Organigram Global’s conference call:

• Record financial performance: Q3 net revenue rose 49% year over year to CAD 105.8 million, while adjusted EBITDA reached a record CAD 13.4 million and adjusted gross margin expanded to 37%. Management expects fiscal 2026 revenue to exceed CAD 350 million, with margins and EBITDA meaningfully above fiscal 2025 levels.
• Sanity Group is scaling as planned: The German business contributed €24.5 million of revenue during OrganiGram’s ownership period, and international sales represented roughly 35% of consolidated revenue. Management expects Sanity’s revenue growth to continue, with operating expenses remaining relatively stable and creating further P&L leverage.
• Canadian product recovery is gaining traction: New vape hardware and higher-potency products helped improve vape share in June, while infused pre-rolls returned to growth. Flower share increased to 12.5% year over year, and beverages and concentrates also posted strong gains as the company reduces its SKU count and focuses on higher-performing products.
• International supply and margin opportunities remain significant: OrganiGram is improving Canadian flower pass rates, adding suppliers, and pursuing EU GMP-compliant remediation pathways to meet tight German demand. EU GMP certification could meaningfully improve margins by reducing reliance on European processing, although no approval timeline was provided.
• Cash flow remains a near-term concern: Free cash flow was negative CAD 3.9 million in Q3, and management expects negative free cash flow for fiscal 2026 because of working-capital investments supporting the larger Sanity-led business. Cash and cash equivalents were CAD 11.7 million at quarter end, although total liquidity including debt facilities was CAD 49.2 million.

Organigram Global Stock Performance

OGI traded down $0.03 during trading hours on Thursday, reaching $1.26. The company’s stock had a trading volume of 483,131 shares, compared to its average volume of 810,468. Organigram Global has a 52 week low of $0.85 and a 52 week high of $2.24. The firm has a market cap of $178.34 million, a PE ratio of 2.75 and a beta of 1.46. The company’s 50-day moving average is $0.99 and its 200-day moving average is $1.23.

Institutional Investors Weigh In On Organigram Global

Several hedge funds have recently added to or reduced their stakes in OGI. Walleye Capital LLC acquired a new stake in Organigram Global during the 4th quarter valued at approximately $25,000. StoneX Group Inc. bought a new stake in Organigram Global during the 4th quarter worth approximately $30,000. HRT Financial LP bought a new position in shares of Organigram Global in the fourth quarter valued at approximately $52,000. Bank of America Corp DE grew its holdings in Organigram Global by 1,678.1% during the third quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock worth $76,000 after buying an additional 35,256 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Organigram Global during the fourth quarter worth about $188,000. 34.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Organigram Global from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Organigram Global in a research report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

About Organigram Global

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.